In clinical studies of the metabolic behavior of radioactively labeled proteins, the turnover (biological half-life or degradation rate) is usually determined from serum (or plasma) concentration curves which entail multiple blood sampling. The amounts of retained isotope are customarily inferred (by difference) from the analyses of excreta obtained from complete 24-hour samples collected for a number of successive days. In the present investigation the turnover of I131-labeled beta and gamma-globulins prepared by chemical fractionation was determined not only by the conventional method of blood and urine sampling but also by a new technique utilizing the whole-body gamma spectrometer. This device permits in vivo measurement of very low levels of an internally deposited gamma emitter (in this case, the I131). The procedure provides an excellent method for measuring retention of labeled globulins over long periods of time following administration of very low levels of isotopes. It also eliminates the tedious radiochemical analyses of excreta.
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PATIENTS AND METHODS
Preparation of I"'-labeled globulins. The globulins used for the turnover studies were prepared from individual serums of 3 subjects. The first preparation was a y2-globulin fractionated by the method of Nichol and Deutsch (1) . The donor was a 38 year old asymptomatic male who, after hospitalization and clinical investigation, was considered a suitable healthy subject. The second preparation was also a y2-globulin fractionated as noted above, but the donor was a patient with an established diagnosis of multiple myeloma, whose paper electrophoretic pattern disclosed a pronounced gamma peak. The third preparation, to be described elsewhere, was a beta globulin from a donor with an established diagnosis of multiple myeloma, whose electrophoretic *This research was supported by the U. S. Atomic Energy Commission.
t Research Collaborator from the Montefiore Hospital, New York, N. Y. pattern showed a distinct beta peac and no gamma globulin.
The homogeneity of the fractionated *bulins was studied by two physicochemical procedures.+ The electrophoretic characterization was carried out in the Spinco model of the Tiselius apparatus and the ultracentrifugal patterns of these same fractions were determined in the Spinco ultracentrifuge. In Figure 1 are shown the paper electrophoretic (a), Tiselius (b), and ultracentrifugation (c and d) determinations of the -Y2 globulin fractionated from the sera of the normal healthy donor, Sm. There is a single peak in the paper strip and in both the ascending and descending limbs of the Tiselius electrophoretic patterns, indicative of a high degree of homogeneity in this 'y2-globulin. The sedimentation constant in (c) for the large peak was calculated as S21,, giving a number of 6.48, corresponding to a molecular weight of about 160,000, which is in the accepted range for gamma globulin. It is to be noted that there is also seen in (c) another small peak representing a non--y2-globulin not separated from the major fraction by the technique employed. The S20 number for this peak was 9.95. In (d) the same preparation as in (c) was run after radioactive iodination but at a lesser concentration, thus showing a smaller peak. The S20 number for this peak was calculated to be 6.64. The result of this determination was considered an indication that by this analysis the iodination with I"31 did not show recognizable denaturation of the y2-globulin. However, it must be noted that the techniques employed do not necessarily show subtler degrees of degradation, as might conceivably be detected by chromatographic analyses of protein with mapping of the location of radioactivity. Figure 2 shows a study carried out in a way similar to that shown in Figure 1 but in this instance using the y2-globulin fractionated from the serum of hypergammaglobulinemic multiple myeloma donor patient L. In this preparation, the S2,, number for the major peaks was 6.60 in (c) and 6.64 in (d) after radioactive iodination. For the small contaminating peak in (c), the number was 9.80.
Iodination, assay and calculations. The globulin preparations were iodinated and their radioactive assays determined as described before for serum and urine concentration curves (2) . This procedure was performed in a well-type scintillation counter using standard electronic components. The number of microcuries in the amount of protein from 2.5 to 4.9 mg. The calculations for determining the turnover consisted in plotting the radioactivity (after correction for physical decay) as a function of the time of sampling on semilogarithmic paper. The rapid early decay of the curve is thought to be due to distribution and mixing of the injected labeled preparation, while the second part of the curve is designated as the slow component. It is an exponential decay indicated by the straight line and is considered to represent the rate of degradation of the injected labeled protein (3).
Patients. The diagnoses of multiple myeloma in the two donors with this disease and in the recipient in whom the turnover studies were carried out were established by microscopic examination of bone marrow aspirations. Chemical determinations of the serum proteins, paper electrophoretic serum patterns and X-ray bone surveys also supported the diagnoses. In the case of the recipient, Lugol's solution was administered 3 days before the injection of the labeled globulin and daily throughout the study to prevent thyroid accumulation of radioactive iodine. The maximal radiation dosage to the recipient was calculated to be 0.013 rad in a 50 kg patient, assuming an effective half-life of 4.3 days and taking the blood as the critical organ (2).
Whole-body counter. A whole-body gamma scintillation spectrometer was utilized in this study for the in zivo detection of gamma radiation. The high quantum efficiency for gamma makes this instrument very valuable for measuring small tracer amounts of radioactive isotopes. The gamma radiation from I'm-labeled globulin retained in the body as a function of time was measured with an energy-sensitive NaI crystal detector. The data from the spectrometer are in the form of pulse-height spectra obtained by analysis of the amplified output of the detector. The information plotted is the counting rate per unit energy interval.
The fact that the output pulse generated by the scintillation detector is proportional to the energy dissipated in the scintillator by the gamma photon gives this counter its greatest advantage. I'" in this study was identified by its distinctive energy spectrum, and the The Brookhaven National Laboratory whole-body counter is built around a 4 X 8 inch NaI (Ti) crystal detector mounted with three 3-inch photomultiplier tubes. This detector is connected to a linear amplifier and by appropriate circuitry to a Penco (model PA-4) 100-channel pulse-height analyzer. The crystal detector is located in a shielded room, 6 X 7 X 9 feet, constructed of 6 inch steel. The interior of this 42 ton room is lined with lead, cadmium and copper for shielding against the low energy components of the background radiation. The heavy shielding effectively reduces the gamma radiation to the detector from both cosmic rays and gammaemitting contaminants in building materials, and increases the signal-to-noise ratio for the system.
The patient is counted in a chair placed in a standard position under the crystal as shown in Figure 3 . The crystal is mounted 19 inches above the apex of the chair so that it "sees" a large fraction of the whole body. This counting position approaches optimal geometry while at the same time assuring to the patient a position which is both comfortable and easily reproducible. The patient was counted immediately before and after i.v. 
RESULTS
The turnover of a beta globulin prepared from the serum of a multiple myeloma patient and la-beled with 1131 is shown in Figure 4 . The recipient in whom the turnover study was performed was a hypergammaglobulinemic patient with multiple myeloma. In curve B the half-time (TI) was determined by the serum concentration method as being 9.9 days and by the urinary excretion method as 8.7 days (curve C). These values are in good agreement and were established by two conventional methods. Throughout the period of these two studies and continuing to the fifty-third day, the patient was placed in the whole-body counter 34 times and the decrease in the radioactivity was determined with progression of time. The Tj established by the wholebody counter method was 10.3 days. The values obtained in curves A and B are essentially the same, while that from C is slightly shorter. This is not unusual for the urinary excretion curve, since it is always possible that a specimen may be lost and because a very small amount of the label appears in the feces and is therefore not accounted for.
In the same recipient for whom the data are shown in Figure 4 and at a subsequent time, this patient was injected with IJ31-y2-globulin prepared from the serum of a hypergammaglobulinemic multiple myeloma patient. In this instance (Figure 5 ) the Tj determined from the urinary excretion data and that from the whole-body counter technique were compared. Instead of counting an aliquot of a 24-hour urine collection in a scintillation well counter, the entire 24-hour urine collection obtained on each of 23 successive days was counted in the whole-body counter. Replicate testing cannot be carried out with these procedures, but the accuracy of the wholebody counter method was determined as shown in Figure 6 . Radioactively labeled beta globulin was injected into the patient as indicated in curve A and the TA was 10.3 days. About 3.5 months later, beta globulin was again labeled, injected into the same patient, and the TA was 9.8 days as seen in curve B. Between those two studies multiple m} elomia gamma globulin was labeled, injected into the same patient, and the T. was 6.3 days (curve C). About 3.5 months after this, the TL for labeled normal gamma globulin was determined and found to be 7 days (curve D). Thus, in a period of about 7 months four turnover stud- Figure  4) . The degradation rate for the gamma globulin (letermined from the whole-body counter method was 11.0 per cent per day and from the urinary excretion data it was 11.6 per cent per day ( Figure 5 ).
To be of value, the whole-body in vzivo gamma spectrometer technique results must compare favorably with those obtained by calculation from serum and urinary excretion radioactivity concentrations. This was demonstrated for both beta and gamma globulin turnovers and in a separate study (unpublished data) for albumin in which the advantages of the whole-body counting method were found to be: 1) elimination of serial blood sampling and collection of excreta for radiochemical analyses; 2) direct determination of body content rather than estimation by difference or extrapolation from fractional measurement; and 3) utilization for tracer studies of very low levels of an internally (leposited gamma emitter over long periods of time.
SUMMARY
The turnover rates of radioactively labeled beta and gamma globulins in a hypergammaglobulinemic multiple myeloma patient were compared by the conventional serum and urinary excretion methods with those found using the in viz'o whole-body gamma spectrometer counting method. The fractionated radioactively labeled globulins used in these studies were considered by free (Tiselius) electrophoresis and ultracentrifugal patterns to have an acceptable degree of homogeneity. The half-life for the beta globulin was 9.9 days by the serum concentration method, 8.7 days by the urinary excretion method and in two different studies by the in vivo whole-body counter method, 10.3 and 9.8 days, respectively. The half-life for the gamma globulin utilizing urinary data was 6.5 days as compared to 6.3 days for the whole-body counter method. By the latter technique, with a different gamma globulin preparation, the halflife was 7.1 days.
